Showing 5581-5590 of 5643 results for "".
- EyePrint Prosthetics Announces Clinical Outcomes Achieved With EyePrintPROhttps://modernod.com/news/eyeprint-prosthetics-announces-clinical-outcomes-achieved-with-eyeprintpro/2480203/EyePrint Prosthetics, a company dedicated to restoring vision to patients who have complex corneal irregularities, announced the clinical outcomes that have been achieved since the EyePrintPRO lens was FDA-cleared 2 y
- ARVO 2018: Genentech Ophthalmology Data Highlightshttps://modernod.com/news/arvo-2018-genentech-ophthalmology-data-highlights/2480204/Genentech will be presenting several studies at the Association for Research in Vision and Ophthalmology (ARVO) meeting on April 29 – May 3 in Honolulu. Data being reported at ARVO continue to show the safety and efficacy of Lucentis (ranibizumab) as a treatment for wet age-related macular degene
- Hill-Rom Enhances Spot Vision Screener to Serve Senior Populationhttps://modernod.com/news/hill-rom-enhances-spot-vision-screener-to-serve-senior-population/2480205/Hill-Rom announced new enhancements to its Welch Allyn Spot Vision Screener, enabling the device to quickly and effectively screen for vision issues in adult patients with pupil sizes as small as 3 mm, according to a company news release. Spot Vision Screener is a handheld, portable device
- Fresenius Kabi Terminates $4.3-Billion Merger Agreement with Akornhttps://modernod.com/news/fresenius-kabi-terminates-4-3-billion-merger-agreement-with-akorn/2480219/Fresenius Kabi announced Sunday that it has decided to abandon its planned takeover of Akorn, citing the latter’s “failure to fulfill
- Lighthouse Guild Offers eLearning Course on Low Vision Assessment for Occupational Therapyhttps://modernod.com/news/lighthouse-guild-offers-elearning-course-on-low-vision-assessment-for-occupational-therapy/2480221/Lighthouse Guild, in partnership with the American Occupational Therapy Association (AOTA), is offering a 2-hour online program designed for occupational therapists in all settings. The course titled “Low Vision Assessment for Occupational Therapy” demonstrates the basic strategies and tools for
- TFOS Recognizes the Bioprotectant Properties of Trehalose, a Component of Thealoz Duo, in the Treatment of Dry Eyehttps://modernod.com/news/tfos-recognizes-the-bioprotectant-properties-of-trehalose-a-component-of-thealoz-duo-in-the-treatment-of-dry-eye/2480223/The TFOS international Dry Eye WorkShop II (TFOS DEWS II), whose report has been published in the July 2017 issue of the Ocular Surface journal, acknowledged that trehalose is an effective ingredient in association with hyaluronic acid for the tre
- Nine Members of Congress Honored for Efforts to Preserve Access to Quality Medical Eye Carehttps://modernod.com/news/nine-members-of-congress-honored-for-efforts-to-preserve-access-to-quality-medical-eye-care/2480228/The American Academy of Ophthalmology is honoring nine members of Congress whose legislative efforts are helping to preserve patient access to quality medical and surgical eye care. The Academy is presenting its 2018 Visionary Awards to Sen. Tom Carper, D-Del., Sen. Lisa Murkowski, R-Alaska, Sen.
- Bausch + Lomb Receives FDA 510(k) Clearance for Boston Scleral Lens Casehttps://modernod.com/news/bausch-lomb-receives-fda-510k-clearance-for-boston-scleral-lens-case/2480229/Bausch + Lomb announced that it has received 510(K) clearance from the FDA for the Boston scleral lens case, a storage case developed specifically for scleral lenses. The case is designed to hold lenses up to 23.5 millimeters in diameter and up to 10.0 millimeters in sagittal depth. The Boston sc
- Data from BioTime’s OpRegen and Retinal Restoration Programs to Be Presented at ARVO 2018https://modernod.com/news/data-from-biotimes-opregen-and-retinal-restoration-programs-to-be-presented-at-arvo-2018/2480231/BioTime announced that data from the ongoing OpRegen clinical trial and Retinal Restoration program will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) meeting taking place from April 29 – May 3, 2018, in Honolulu, Hawaii. The scheduled times (note
- EyePoint Pharmaceuticals’ Yutiq for Posterior Segment Uveitis to be Presented at the 2018 ARVO Annual Meetinghttps://modernod.com/news/eyepoint-pharmaceuticals-yutiq-for-posterior-segment-uveitis-to-be-presented-at-the-2018-arvo-annual-meeting/2480232/EyePoint Pharmaceuticals announced that two abstracts supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for noninfectious posterior segment uveitis have been accepted for presentation at the Association for Research in Vision and Ophtha